Neuronetics Plans Expanded Marketing For Transcranial Magnetic Stimulation Depression Therapy

Despite a recent negative Blue Cross Blue Shield technology assessment, Neuronetics is moving ahead with plans to expand sales and marketing efforts for its NeuroStar transcranial magnetic stimulation therapy for drug-resistant depression.